News Article

Vespa Capital has announced its investment in FibroFind, a globally recognised pre-clinical contract research organisation. FibroFind has developed a unique, patented Precision Cut Tissue Slice (PCTS) platform, which offers significantly enhanced translational accuracy compared to traditional models.

Candesic is pleased to have provided vendor commercial due diligence to FibroFind in support of Vespa Capital ’s investment. The Candesic team was led by Senior Partner Dr Michelle Tempest, Senior Engagement Manager Jack Zeng and Engagement Manager Blake Edwards.

“We are incredibly grateful to the team at Candesic for their outstanding work on the commercial due diligence for FibroFind. Their depth of insight, strategic thinking and ability to rapidly grasp the nuances of our platform were exceptional…We could not have asked for a better partner at such a pivotal moment for the company,” said Jelena Mann, CEO at FibroFind. Rob Sowood, Investment Director at Vespa Capital also added “Your report was really valuable in helping us understand the market and how the technology works.”